Expression of p53R2, newly p53 target in oral normal epithelium, epithelial dysplasia and squamous cell carcinoma

Cancer Letters

Volumn 190, Issue 2, 2003, Pages 233-243

  Yanamoto, Souichi ^a   Kawasaki, Goro ^a   Yoshitomi, Izumi ^a   Mizuno, Akio ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

Dysplasia; Oral; p53; p53R2; Squamous cell carcinoma

Indexed keywords

CARBOPLATIN; CISPLATIN; KI 67 ANTIGEN; MESSENGER RNA; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; TEGAFUR;

AGED; ARTICLE; BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURGERY; CARCINOGENESIS; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; DYSPLASIA; FEMALE; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; MOUTH MUCOSA; NUCLEOTIDE SEQUENCE; P53R2 GENE; POLYMERASE CHAIN REACTION; PREDICTION; PREOPERATIVE RADIOTHERAPY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RADIATION RESPONSE; RADIOSENSITIVITY; SINGLE STRAND CONFORMATION POLYMORPHISM; SQUAMOUS CELL CARCINOMA;

EID: 0037455925     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(02)00588-8     Document Type: Article

References (35)

1. Parkin D.M., Pisani P., Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int. J. Cancer. 80:1999;827-841.
2. Jacobs C. The internist in the management of head and neck cancer. Am. Intern. Med. 113:1990;771-781.
3. Peters L.J., Brock W.A., Chapman J.D., Wilson G. Predictive assays of tumor radiocurability. Am. J. Clin. Oncol. 11:1988;275-287.
4. Nair M.K., Sankaranarayanan R., Krishnan E., Padmanabhan T.K., Mayadevi S., Mathew A. Independent predictors of response and disease-free survival in oral cancer treated with radical radiation therapy. Cancer. 69:1992;2221-2226.
5. Raybaud-Diogene H., Fortin A., Morency R., Roy J., Monteil R.A., Tetu A. Markers of radioresistance in squamous cell carcinomas of the head and neck: A clinicopathologic and immunohistochemical study. J. Clin. Oncol. 15:1997;1030-1038.
6. INK4A expression predict reduced survival in carcinoma of the anterior tongue. Clin. Cancer Res. 5:1999;2810-2819.
7. Koelbl O., Rosenwald A., Haberl M., Muller J., Reuther J., Flentje M. p53 and Ki-67 as predictive markers for radiosensitivity in squamous cell carcinoma of the oral cavity? An immunohistochemical and clinicopathologic study. Head Neck. 49:2001;147-154.
8. Ravi D., Ramadas K., Mathew B.S., Panikkar K.R., Nair M.K., Pillai M.R. Apoptosis, angiogenesis and proliferation: trifunctional measure of tumor response to radiotherapy for oral cancer. Oral Oncol. 37:2001;164-171.
9. Rawal R.M., Patel P.S., Vyas R.K., Sainger R.N., Shah M.H., Peshavariya H.M., Patel D.D., Bhatavdekar J.M. Role of pretherapeutic biomarkers in predicting postoperative radiotherapy response in patients with advanced squamous cell carcinoma. Int. J. Radiat. Biol. 77:2001;1141-1146.
10. Osman I., Drobnjak M., Fazzari M., Ferrara J., Scher H.I., Cordon-Cardo C. Inactivation of the p53 pathway in prostate cancer: impact on tumor progression. Clin. Cancer Res. 5:1999;2082-2088.
11. Pfister C., Larue H., Moore L., Lacombe L., Veilleux C., Tetu B., Meyer F., Fradet Y. Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes. Int. J. Cancer. 89:2000;100-104.
12. Koontongkaew S., Chareonkitkajorn L., Chanvitan A., Leelakriangsak M., Amornphimoltham P. Alterations of p53, pRb, cyclin D1 and cdk4 in human oral and pharyngeal squamous cell carcinomas. Oral Oncol. 36:2000;334-339.
13. Kato H., Yoshikawa M., Fukai Y., Tajima K., Masuda N., Tsukada K., Kuwano H., Nakajima T. An immunohistochemical study of p16, pRb, p21 and p53 proteins in human esophageal cancers. Anticancer Res. 20:2000;345-350.
14. Marx J. Many gene changes found in cancer. Science. 246:1989;1386-1388.
15. Fearon E.R., Vogelstein B. Genetic model for colorectal tumorigenesis. Cell. 61:1990;759-767.
16. Tanaka H., Arakawa H., Yamaguchi T., Shiraishi K., Fukuda S., Matsui K., Takei Y. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature. 404:2000;42-49.
17. Nakano K., Balint E., Ashcroft M., Vousden K.H. A ribonucleotide reductase gene is a transcriptional target of p53 and p73. Oncogene. 19:2000;4283-4289.
18. Yamaguchi T., Matsuda K., Sagiya Y., Iwadate M., Fujino M.A., Nakamura Y., Arakawa H. p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle checkpoint. Cancer Res. 61:2001;8256-8262.
19. Byun D.S., Chae K.S., Ryu B.K., Lee M.G., Chi S.G. Expression and mutation analysis of p53R2, a newly identified p53 target for DNA repair in human gastric carcinoma. Int. J. Cancer. 98:2002;718-723.
20. UICC TNM Classification of Malignant Tumors. Sobin L.H., Wittekind C. 5th Edition: 1997;88-90 Springer, Berlin.
21. Pindborg J.J., Reichart P.A., Smith C.J., van der Waal I. Histological Typing of Cancer and Precancer of the Oral Mucosa. 1997;Springer, Berlin.
22. Shintani S., Mihara M., Ueyama Y., Matsumura T., Wong D.T.W. Cyclin D1 overexpression associates with radiosensitivity in oral squamous cell carcinoma. Int. J. Cancer. 96:2001;159-165.
23. Levine A.J., Perry M.E., Chang A., Silver A., Dittmer D., Wu M., Welsh D. The 1993 Walter Hubert Lecture: the role of the p53 tumor-suppressor gene in tumorigenesis. Br. J. Cancer. 69:1994;409-416.
24. Esrig D., Spruck C.H. 3rd, Nichols P.W., Chaiwun B., Steren K., Groshen S., Chen S.C., Skinner D.G., Jones P.A., Cote R.J. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am. J. Pathol. 143:1993;1389-1397.
25. Sherr C.J. Tumor surveillance via the ARF-p53 pathway. Genes Dev. 12:1998;2984-2991.
26. Ng I.O.L., Lam K.Y., Ng M., Regezi J.A. Expression of p21/waf1 in oral squamous cell carcinomas-correlation with p53 and mdm2 and cellular proliferation index. Oral Oncol. 35:1999;63-69.
27. Agarwal S., Mathur M., Srivastava A., Ralhan R. MDM2/p53 co-expression in oral premalignant and malignant lesions: potential prognostic implications. Oral Oncol. 35:1999;209-216.
28. Bundgaad T., Bentzen S.M., Wildt J., Sørensen F.B., Søgaard H., Nielsen J.E. Histopathologic, stereologic, epidemiologic and clinical parameters in the prognostic evaluation of squamous cell carcinoma of the oral cavity. Head Neck. 18:1996;142-152.
29. Gilbert E.H., Goffinet D.R., Bagshaw M.A. Carcinoma of the oral tongue and floor of mouth: fifteen years' experience with liner acceleration therapy. Cancer. 35:1975;1517-1524.
30. Kowalski L.P., Bagietto R., Lara J.R.L., Santos R.L., Silva J.F., Magrin J. Prognostic significance of the distribution of neck node metastasis from oral carcinoma. Head Neck. 22:2000;207-214.
31. Alsner J., Sørensen S.B., Overgaard J. TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck. Radiother. Oncol. 59:2001;179-185.
32. Brown J.M., Wouters B.G. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 59:1999;1391-1399.
33. Finkel E. Does cancer therapy trigger cell suicide? Science. 286:1999;2256-2258.
34. Danielsen T., Smith-Sørensen B., Grønlund H.A., Hvidsten M., Børresen-Dale A.L., Rofstad E.K. No association between radiosensitivity and TP53 status, G1 arrest or protein levels of p53, myc, ras or raf in human melanoma lines. Int. J. Radiat. Biol. 75:1999;1149-1160.
35. Schuler B.M., Herrmann R., De Greve J.L.P., Stewart A.K., Gatzemeier U., Stewart D.J., Laufman L., Gralla R., Kuball J., Buhl R., Heussel C.P., Kommoss F., Perruchoud A.P., Shepherd F.A., Fritz M.A., Horowitz J.A., Huber C., Rochlitz C. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. J. Clin. Oncol. 19:2001;1750-1758.